292 related articles for article (PubMed ID: 1374810)
21. The neutralization relationship of HIV type 1, HIV type 2, and SIVcpz is reflected in the genetic diversity that distinguishes them.
Nyambi PN; Willems B; Janssens W; Fransen K; Nkengasong J; Peeters M; Vereecken K; Heyndrickx L; Piot P; van der Groen G
AIDS Res Hum Retroviruses; 1997 Jan; 13(1):7-17. PubMed ID: 8989422
[TBL] [Abstract][Full Text] [Related]
22. Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.
Warren RQ; Anderson SA; Nkya WM; Shao JF; Hendrix CW; Melcher GP; Redfield RR; Kennedy RC
J Virol; 1992 Sep; 66(9):5210-5. PubMed ID: 1380094
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.
Earl PL; Sugiura W; Montefiori DC; Broder CC; Lee SA; Wild C; Lifson J; Moss B
J Virol; 2001 Jan; 75(2):645-53. PubMed ID: 11134278
[TBL] [Abstract][Full Text] [Related]
24. Specificity of antipeptide antibodies produced against V2 and V3 regions of the external envelope of human immunodeficiency virus type 2.
Babas T; Benichou S; Guetard D; Montagnier L; Bahraoui E
Mol Immunol; 1994 Apr; 31(5):361-9. PubMed ID: 8152439
[TBL] [Abstract][Full Text] [Related]
25. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
Krachmarov C; Pinter A; Honnen WJ; Gorny MK; Nyambi PN; Zolla-Pazner S; Kayman SC
J Virol; 2005 Jan; 79(2):780-90. PubMed ID: 15613306
[TBL] [Abstract][Full Text] [Related]
26. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
Davis D; Stephens DM; Carne CA; Lachmann PJ
J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
[TBL] [Abstract][Full Text] [Related]
27. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.
Yuste E; Sanford HB; Carmody J; Bixby J; Little S; Zwick MB; Greenough T; Burton DR; Richman DD; Desrosiers RC; Johnson WE
J Virol; 2006 Mar; 80(6):3030-41. PubMed ID: 16501112
[TBL] [Abstract][Full Text] [Related]
28. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
Moore JP; Ho DD
J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
[TBL] [Abstract][Full Text] [Related]
29. New multiple antigenic peptide-based enzyme immunoassay for detection of simian immunodeficiency virus infection in nonhuman primates and humans.
Ndongmo CB; Switzer WM; Pau CP; Zeh C; Schaefer A; Pieniazek D; Folks TM; Kalish ML
J Clin Microbiol; 2004 Nov; 42(11):5161-9. PubMed ID: 15528710
[TBL] [Abstract][Full Text] [Related]
30. Fine analysis of humoral antibody response to envelope glycoprotein of SIV in infected and vaccinated macaques.
Silvera P; Flanagan B; Kent K; Rud E; Powell C; Corcoran T; Bruck C; Thiriart C; Haigwood NL; Stott EJ
AIDS Res Hum Retroviruses; 1994 Oct; 10(10):1295-304. PubMed ID: 7848685
[TBL] [Abstract][Full Text] [Related]
31. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
[TBL] [Abstract][Full Text] [Related]
32. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
[TBL] [Abstract][Full Text] [Related]
33. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.
Clements JE; Montelaro RC; Zink MC; Amedee AM; Miller S; Trichel AM; Jagerski B; Hauer D; Martin LN; Bohm RP
J Virol; 1995 May; 69(5):2737-44. PubMed ID: 7707496
[TBL] [Abstract][Full Text] [Related]
34. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
[TBL] [Abstract][Full Text] [Related]
35. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
Kayman SC; Wu Z; Revesz K; Chen H; Kopelman R; Pinter A
J Virol; 1994 Jan; 68(1):400-10. PubMed ID: 7504740
[TBL] [Abstract][Full Text] [Related]
36. Comparison of linear antigenic sites in the envelope proteins of human immunodeficiency virus (HIV) type 2 and type 1.
Norrby E; Putkonen P; Böttiger B; Utter G; Biberfeld G
AIDS Res Hum Retroviruses; 1991 Mar; 7(3):279-85. PubMed ID: 1712215
[TBL] [Abstract][Full Text] [Related]
37. Characterization of simian-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys.
Etemad-Moghadam B; Karlsson GB; Halloran M; Sun Y; Schenten D; Fernandes M; Letvin NL; Sodroski J
J Virol; 1998 Oct; 72(10):8437-45. PubMed ID: 9733899
[TBL] [Abstract][Full Text] [Related]
38. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies.
Kent KA; Rud E; Corcoran T; Powell C; Thiriart C; Collignon C; Stott EJ
AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1147-51. PubMed ID: 1380261
[TBL] [Abstract][Full Text] [Related]
39. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
Cheng-Mayer C; Brown A; Harouse J; Luciw PA; Mayer AJ
J Virol; 1999 Jul; 73(7):5294-300. PubMed ID: 10364275
[TBL] [Abstract][Full Text] [Related]
40. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection.
Lewis MG; Elkins WR; McCutchan FE; Benveniste RE; Lai CY; Montefiori DC; Burke DS; Eddy GA; Shafferman A
Vaccine; 1993 Oct; 11(13):1347-55. PubMed ID: 7507625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
